COMPARE · Data as of August 24, 2026
EXEL vs REGN
Verdict: Side-by-side breakdown using the Bull Rankings model. EXEL scored 74.0, REGN scored 64.0 — EXEL leads.
Compare another set
EXEL
Exelixis, Inc.
74
$56.08 · $13.9B
fundamentals as of
Score gap
10.0
EXEL leads
REGN
Regeneron Pharmaceuticals, Inc.
64
$835.34 · $86.0B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestEXEL17.6x
- Fastest growthREGN+9.3%
- Strongest balance sheetREGN0.09
- Highest qualityEXEL97 / 100
- Largest discount to fair valueEXEL-40%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
EXEL
stronger →← stronger
REGN
97
Qualityreturns · margins · balance sheet
66
80
Growthrevenue & earnings expansion
79
52
Valuevaluation vs sector peers
50
EXEL is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
EXEL
REGN
$1.2bC+
FCF
$3.8bB
+9.2%B
Rev
+9.3%B
0.09B+
D/E
0.09B+
17.6xA-
P/E
20.7xB+
2.56C
PEG
1.38B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
EXEL
REGN
40% below
Price vs fair valuelower is cheaper
24% above
~-2%/yr
Growth the price implies10-yr FCF · lower = less priced in
~14%/yr
+40%
1-yr DCF upside
-29%
+65%
5-yr DCF upside
-19%
+111%
10-yr DCF upside
-3%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
EXEL
Why this score
- Buying back stock
- Durable high returns
REGN
Why this score
- Diluting shareholders
The companies
EXELExelixis, Inc.
Why now
Biotechnology · market cap $13.9b. Trading near 52-week high of $57.57 — momentum setup, limited technical margin of safety. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $53.00 (implying -5% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 47% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 136% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
REGNRegeneron Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $86.0b. Trading near 52-week high of $847.00 — momentum setup, limited technical margin of safety. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $840.43 (implying +1% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 14% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $86.0b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where EXEL and REGN diverge
On the headline score the gap is 10.0 points in favor of EXEL. The widest single difference is Quality, where EXEL leads by 30.5 points.
- QualityEXEL 96.8 · REGN 66.3EXEL +30.5
- ValueEXEL 52.3 · REGN 50.4level
- GrowthEXEL 80.0 · REGN 78.6level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.